Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Gozlan

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Biochemical Pharmacology|October 1, 1990
Common pharmacological and physico-chemical properties of 5-HT3 binding sites in the rat cerebral cortex and NG 108-15 clonal cellsF J Bolaños, L E Schechter, M C Miquel, et al.
Clinical Neuropharmacology|October 1, 1987
Chronic chlorimipramine does not reverse the reduction of cerebrospinal fluid Met-enkephalin-like immunoreactivity in chronic-pain patientsS Bourgoin, F Cesselin, H Gozlan, et al.
Neurobiology of Aging|July 1, 1990
Aging associated changes in serotoninergic and dopaminergic pre- and postsynaptic neurochemical markers in the rat brainH Gozlan, G Daval, D Verge, et al.
Brain Research|July 29, 1985
Spontaneous and evoked release of methionine-enkephalin-like material from the rat spinal cord in vivoF Cesselin, D Le Bars, S Bourgoin, et al.
Brain Research|May 28, 1993
5-HT3 receptors in the rat central nervous system are mainly located on nerve fibres and terminalsE J Kidd, A M Laporte, X Langlois, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1993
New methoxy-chroman derivatives, 4[N-(5-methoxy-chroman-3-yl)N- propylamino]butyl-8-azaspiro-(4,5)-decane-7,9-dione [(+/-)-S 20244] and its enantiomers, (+)-S 20499 and (-)-S 20500, with potent agonist properties at central 5-hydroxytryptamine1A receptorsE J Kidd, S Haj-Dahmane, T Jolas, et al.
Neuroreport|June 1, 1992
Anxiolytic-like actions of anpirtoline in a mouse light-dark aversion paradigmP Metzenauer, N M Barnes, B Costall, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|March 1, 1992
Characterization of a novel 5-HT4 receptor antagonist of the azabicycloalkyl benzimidazolone class: DAU 6285A Dumuis, H Gozlan, M Sebben, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1990
Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studiesL E Schechter, F J Bolaños, H Gozlan, et al.
Brain Research|May 3, 1988
Lesion of dopaminergic terminals in the amygdala produces enhanced locomotor response to D-amphetamine and opposite changes in dopaminergic activity in prefrontal cortex and nucleus accumbensH Simon, K Taghzouti, H Gozlan, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Biochemical Pharmacology|October 1, 1990
Common pharmacological and physico-chemical properties of 5-HT3 binding sites in the rat cerebral cortex and NG 108-15 clonal cellsF J Bolaños, L E Schechter, M C Miquel, et al.
Clinical Neuropharmacology|October 1, 1987
Chronic chlorimipramine does not reverse the reduction of cerebrospinal fluid Met-enkephalin-like immunoreactivity in chronic-pain patientsS Bourgoin, F Cesselin, H Gozlan, et al.
Neurobiology of Aging|July 1, 1990
Aging associated changes in serotoninergic and dopaminergic pre- and postsynaptic neurochemical markers in the rat brainH Gozlan, G Daval, D Verge, et al.
Brain Research|July 29, 1985
Spontaneous and evoked release of methionine-enkephalin-like material from the rat spinal cord in vivoF Cesselin, D Le Bars, S Bourgoin, et al.
Brain Research|May 28, 1993
5-HT3 receptors in the rat central nervous system are mainly located on nerve fibres and terminalsE J Kidd, A M Laporte, X Langlois, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1993
New methoxy-chroman derivatives, 4[N-(5-methoxy-chroman-3-yl)N- propylamino]butyl-8-azaspiro-(4,5)-decane-7,9-dione [(+/-)-S 20244] and its enantiomers, (+)-S 20499 and (-)-S 20500, with potent agonist properties at central 5-hydroxytryptamine1A receptorsE J Kidd, S Haj-Dahmane, T Jolas, et al.
Neuroreport|June 1, 1992
Anxiolytic-like actions of anpirtoline in a mouse light-dark aversion paradigmP Metzenauer, N M Barnes, B Costall, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|March 1, 1992
Characterization of a novel 5-HT4 receptor antagonist of the azabicycloalkyl benzimidazolone class: DAU 6285A Dumuis, H Gozlan, M Sebben, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1990
Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studiesL E Schechter, F J Bolaños, H Gozlan, et al.
Brain Research|May 3, 1988
Lesion of dopaminergic terminals in the amygdala produces enhanced locomotor response to D-amphetamine and opposite changes in dopaminergic activity in prefrontal cortex and nucleus accumbensH Simon, K Taghzouti, H Gozlan, et al.
Pageof 10